Development Pipeline

DNX

DNX-2401 for Glioblastoma
Monotherapy (planned)
 
Combined with Pembrolizumab (Keytruda®)*
 
Combined with Temozolomide (Temodar®)
 
Combined with Interferon Gamma (Actimmune®)
 

Armed DNX

DNX-2440 for Solid Tumors
Monotherapy
 
DNX-2450 for Solid Tumors
Monotherapy
 

MYX

MYX-135 for Hematological Malignancies
Monotherapy
 

DNX-2401

DNX-2401 is an oncolytic immunotherapy designed to fulfill the dual requirements of high potency and safety. To accomplish this, two stable genetic changes in the adenovirus genome were engineered that cause it to replicate selectively in retinoblastoma (Rb) pathway deficient cells and infect tumor cells efficiently. Results from pre-clinical and clinical studies indicate that DNX-2401 (1) replicates in human tumors (2) elicits tumor necrosis (3) triggers intratumoral immune cell infiltration, and (4) can lead to long term tumor destruction. DNX-2401 has been granted Fast Track and Orphan designation by the FDA.

learn about DNX-2401 clinical trials >

DNX-2440

Armed with OX40L

DNX-2440 is the first Armed DNX virus in development for solid tumors. It combines the clinically effective and safe viral backbone of the DNX technology with the expression of a potent immune-modulator, OX40 ligand (OX40L). OX40 is a member of the tumor necrosis factor receptor superfamily, and interactions between OX40 and OX40L act as co-stimulatory signals for T-cell activation. The augmentation of this interaction enhances antitumor immunity.

DNX-2450

Armed with undisclosed t-cell stimulator

DNX-2450, is an Armed DNX virus in development for solid tumors. It combines the clinically effective and safe viral backbone of the DNX technology with the expression of an undisclosed T-cell stimulator that can enhance antitumor immunity.

MYX-135

MYX-135 is a novel oncolytic immunotherapy designed to treat hematological malignancies after myeloablative chemotherapy. MYX-135 is a myxoma virus that cannot infect normal human cells but destroys cancer cells with high efficiency.